MedTrace Logo

Safety and Efficacy of Urinary Kallidinogenase for Large Artery Atherosclerosis Acute Ischemic Stroke

NCT06137300 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 986

Last updated 2024-02-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of urinary kallidinogenase treatment in patients with large artery atherosclerotic acute ischemic stroke.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

Urinary kallidinogenase for injection

Urinary kallidinogenase 0.15PNA once daily for 7 days.

OTHER

Guideline-prescribed medical therapy

Guideline-prescribed medical therapy

Sponsors & Collaborators

  • Yi Yang

    lead OTHER

Principal Investigators

  • Yi Yang, MD,PhD · The First Hospital of Jilin University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-15
Primary Completion
2026-06-30
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06137300 on ClinicalTrials.gov